EFPIA and APRaD sign letter of intent to advance Ukraine's health care

9 March 2015

On March 3, the Ministry of Health of Ukraine and international research-based pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Association of Pharmaceutical Research and Development (APRAD) entered into a Letter of Intent.

On behalf of the Ministry of Health of Ukraine, the document was signed by the Minister of Health of Ukraine, Oleksandr Kvitashvili and, on behalf of industry, by EFPIA director general, Richard Bergström and APRAD executive director Volodymyr Redko.

The negotiations on the possibility of signing this significant document for reforming the health care system of Ukraine began at the end of last year. The determining factor in the decision-making process was a high level meeting between MoH Minister, Mr Kvitashvili, and the executive staff of the EFPIA and APRAD, which took place on December 10, 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK